Center-Authored Papers

Filters: Author is Garcia-Manero, Guillermo  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Y
Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E.  2008.  Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.. Leukemia research. 32(10):1505-9. Abstract
Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E.  2008.  Relapse and death during first remission in acute myeloid leukemia.. Haematologica. 93(4):633-4.
S
Strom SS, Estey E, Outschoorn UM, Garcia-Manero G.  2010.  Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients.. Leukemia & lymphoma. 51(4):598-605. Abstract
Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X et al..  2016.  Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.. BMC cancer. 16:652. Abstract
Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C et al..  2011.  Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(15):1963-70. Abstract
R
Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W et al..  2009.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(4):504-10. Abstract
K
Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L et al..  2013.  Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(21):2662-70. Abstract
H
Hoshino K, Quintás-Cardama A, Radich JP, Dai H, Yang H, Garcia-Manero G.  2009.  Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia.. Leukemia research. 33(10):1361-6. Abstract
G
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD et al..  2011.  Myelodysplastic syndromes.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(1):30-56. Abstract
Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE et al..  2017.  Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(1):60-87. Abstract
Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT et al..  2015.  Myelodysplastic syndromes, version 2.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(3):261-72. Abstract
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G et al..  2013.  Myelodysplastic syndromes: clinical practice guidelines in oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(7):838-74. Abstract
Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.  2008.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(35):5684-8. Abstract
Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U et al..  2016.  Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.. The Lancet. Oncology. Abstract
C
Cogle CR, Scott BL, Boyd T, Garcia-Manero G.  2015.  Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.. The oncologist. Abstract
B
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K et al..  2014.  Gemtuzumab Ozogamicin with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor (FLAG-GO) As Front-line Regimen in Patients with Core Binding Factor Acute Myelogenous Leukemia.. American journal of hematology. 89(10):964-8. Abstract
Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A et al..  2016.  Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.. Cancer. 122(12):1871-9. Abstract
Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH.  2008.  Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.. Cancer. 113(11):3181-5. Abstract
A
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S et al..  2017.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.. Blood. 129(10):1275-1283. Abstract